Nimbus on cloud 9 as psoriasis data support taking rival to Bristol Myers' Sotyktu into phase 3

Nimbus Therapeutics is ramping up its pursuit of Bristol Myers Squibb’s plaque psoriasis drug Sotyktu, committing to moving a rival TYK2 inhibitor into phase 3 after hitting the primary endpoint in a midstage study.